X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7793) 7793
Publication (836) 836
Newsletter (138) 138
Book Review (136) 136
Newspaper Article (115) 115
Book Chapter (52) 52
Conference Proceeding (10) 10
Dissertation (8) 8
Book / eBook (6) 6
Data Set (6) 6
Magazine Article (5) 5
Trade Publication Article (3) 3
Transcript (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4602) 4602
index medicus (4504) 4504
animals (3457) 3457
fibroblasts (3117) 3117
male (2265) 2265
female (1879) 1879
mice (1609) 1609
research (1246) 1246
medicine (1179) 1179
expression (1100) 1100
middle aged (1087) 1087
gene expression (1071) 1071
cells, cultured (1056) 1056
proteins (1013) 1013
research article (1012) 1012
growth factors (991) 991
rats (979) 979
multidisciplinary sciences (963) 963
cell biology (943) 943
adult (938) 938
fibroblasts - metabolism (922) 922
cancer (883) 883
inflammation (867) 867
oncology (855) 855
apoptosis (835) 835
science (823) 823
rodents (812) 812
collagen (810) 810
fibrosis (798) 798
fibroblast growth factors (794) 794
fibroblasts - drug effects (789) 789
health aspects (774) 774
aged (771) 771
care and treatment (741) 741
physiological aspects (727) 727
stem cells (697) 697
analysis (684) 684
angiogenesis (651) 651
cells (642) 642
in-vitro (630) 630
cytokines (627) 627
biology (624) 624
medicine, research & experimental (620) 620
kinases (615) 615
signal transduction (600) 600
studies (598) 598
article (591) 591
surgery (538) 538
biochemistry & molecular biology (537) 537
disease models, animal (527) 527
wound healing (523) 523
physiology (494) 494
oxidative stress (480) 480
skin (477) 477
pharmacology & pharmacy (471) 471
cell line (462) 462
cell proliferation (460) 460
fibroblast-growth-factor (460) 460
risk factors (455) 455
genetic aspects (454) 454
fibroblasts - cytology (453) 453
activation (450) 450
metabolism (450) 450
time factors (445) 445
disease (439) 439
gene-expression (435) 435
extracellular matrix (434) 434
mice, inbred c57bl (434) 434
review (432) 432
fibroblast growth factor (426) 426
tumors (419) 419
proliferation (410) 410
treatment outcome (408) 408
immunology (402) 402
fibroblasts - pathology (399) 399
medical research (397) 397
rats, sprague-dawley (393) 393
transplantation (375) 375
patients (371) 371
biochemistry (363) 363
immunohistochemistry (361) 361
vascular endothelial growth factor (361) 361
in-vivo (356) 356
therapy (344) 344
cell proliferation - drug effects (341) 341
growth (339) 339
differentiation (338) 338
inhibition (337) 337
mortality (335) 335
respiratory system (334) 334
pathogenesis (329) 329
biotechnology & applied microbiology (328) 328
fibroblast growth factors - blood (322) 322
phosphorylation (319) 319
dermatology (313) 313
growth-factor (313) 313
clinical trials (312) 312
heart (312) 312
cytotoxicity (307) 307
usage (307) 307
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8022) 8022
Japanese (18) 18
Chinese (16) 16
French (9) 9
German (9) 9
Spanish (5) 5
Russian (3) 3
Hungarian (2) 2
Korean (2) 2
Polish (2) 2
Portuguese (2) 2
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Hebrew (1) 1
Italian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Supportive Care in Cancer, ISSN 0941-4355, 01/2013, Volume 21, Issue 1, pp. 343 - 355
The aim of this project was to review the literature and define clinical practice guidelines for the use of cytokines and growth factor agents for the... 
Pain Medicine | Rehabilitation Medicine | Nursing | Mucositis | Medicine & Public Health | Cytokines | Oncology | Systematic review | Growth factors | Nursing Management/Nursing Research | Guidelines | FACTOR GM-CSF | COLONY-STIMULATING FACTOR | AUTOLOGOUS HEMATOPOIETIC SCT | VERSUS-HOST-DISEASE | CLINICAL-PRACTICE GUIDELINES | ONCOLOGY | FLUOROURACIL-BASED CHEMOTHERAPY | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | PLACEBO-CONTROLLED TRIAL | HIGH-DOSE CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | RADIATION-INDUCED MUCOSITIS | Granulocyte Colony-Stimulating Factor - adverse effects | Cytokines - therapeutic use | Fibroblast Growth Factors - adverse effects | Mouthwashes | Humans | Evidence-Based Medicine | Granulocyte Colony-Stimulating Factor - therapeutic use | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Stomatitis - etiology | Neoplasms - drug therapy | Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects | Stomatitis - therapy | Fibroblast Growth Factor 7 - therapeutic use | Neoplasms - complications | Fibroblast Growth Factor 7 - adverse effects | Stomatitis - prevention & control | Neoplasms - radiotherapy | Intercellular Signaling Peptides and Proteins - therapeutic use | Intercellular Signaling Peptides and Proteins - adverse effects | Cytokines - adverse effects | Fibroblast Growth Factors - therapeutic use | Practice Guidelines as Topic | Cancer patients | Care and treatment | Stomatitis | Chemotherapy | Stem cells | Macrophage colony stimulating factor | Cancer | Side effects | Preventive medicine | Cancer therapies | Mouth | Mucous membrane | Klinisk medicin | Clinical Medicine
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2017, Volume 19, Issue 12, pp. 1762 - 1772
Aims To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐05231023, a long‐acting fibroblast growth factor 21 (FGF21) analogue, in... 
fibroblast growth factor 21 | IGF‐1 | blood pressure | heart rate | type 2 diabetes | bone biomarkers | IGF-1 | FATTY LIVER-DISEASE | ENERGY-EXPENDITURE | PF-05231023 | PROFILE | PHARMACOKINETICS | ENDOCRINOLOGY & METABOLISM | MICE | FGF21 | Hypertriglyceridemia - drug therapy | Fibroblast Growth Factors - adverse effects | Follow-Up Studies | Obesity - drug therapy | Species Specificity | Humans | Middle Aged | Half-Life | Anti-Obesity Agents - adverse effects | Male | Obesity - blood | Anti-Obesity Agents - therapeutic use | Bone Remodeling - drug effects | Delayed-Action Preparations - administration & dosage | Dose-Response Relationship, Drug | Anti-Obesity Agents - pharmacokinetics | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Fibroblast Growth Factors - administration & dosage | Hypertension - chemically induced | Delayed-Action Preparations - pharmacokinetics | Female | Drug Resistance | Fibroblast Growth Factors - therapeutic use | Body Mass Index | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Hypolipidemic Agents - adverse effects | Anti-Obesity Agents - administration & dosage | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Drug Administration Schedule | Obesity - complications | Biomarkers - blood | Hypertension - physiopathology | Hypertriglyceridemia - blood | Animals | Fibroblast Growth Factors - pharmacokinetics | Delayed-Action Preparations - adverse effects | Hypertriglyceridemia - complications | Hypolipidemic Agents - administration & dosage | Delayed-Action Preparations - therapeutic use | Hypolipidemic Agents - therapeutic use | Infusions, Intravenous | Hypolipidemic Agents - pharmacokinetics | Type 2 diabetes | Obesity | Heart beat | Blood cholesterol | Collagen | Analysis | Body weight | Primates | Fibroblast growth factors | Blood pressure | Fibroblast growth factor | Pharmacodynamics | Diabetes mellitus | Homeostasis | Lipids | Triglycerides | Body weight loss | Bone turnover | Monkeys & apes | Cholesterol | Adiponectin | Heart rate | Rodents | Fibroblasts | Atorvastatin | Lead | Safety | Pharmacokinetics | Growth factors | Diabetes mellitus (non-insulin dependent) | Lipoproteins (high density)
Journal Article
Journal Article
International Immunopharmacology, ISSN 1567-5769, 03/2015, Volume 25, Issue 1, pp. 74 - 82
Journal Article
SCIENCE TRANSLATIONAL MEDICINE, ISSN 1946-6234, 07/2014, Volume 6, Issue 247, pp. 247ra100 - 247ra100
Hepatic accumulation of bile acids is central to the pathogenesis of cholestatic liver diseases. Endocrine hormone fibroblast growth factor 19 (FGF19) may... 
MEDICINE, RESEARCH & EXPERIMENTAL | HEPATOCELLULAR-CARCINOMA | HORMONE | INTRAHEPATIC CHOLESTASIS | PRIMARY BILIARY-CIRRHOSIS | FARNESOID-X-RECEPTOR | FIBROBLAST-GROWTH-FACTOR | BILE-ACID SYNTHESIS | MICE | EXPRESSION | CANCER | CELL BIOLOGY | Recombinant Proteins - therapeutic use | Fibroblast Growth Factors - adverse effects | Liver - pathology | Humans | Middle Aged | Fibroblast Growth Factors - genetics | Male | Cholagogues and Choleretics - adverse effects | Cholestenones - blood | Fibroblast Growth Factors - biosynthesis | Cholestasis, Intrahepatic - drug therapy | Healthy Volunteers | RNA, Messenger - metabolism | Cholagogues and Choleretics - therapeutic use | Genetic Variation | Young Adult | Liver - drug effects | Adult | Liver Neoplasms - pathology | Cholestasis, Extrahepatic - pathology | Disease Models, Animal | Fibroblast Growth Factors - therapeutic use | Gene Transfer Techniques | Cholestasis, Intrahepatic - genetics | Double-Blind Method | Liver Neoplasms - genetics | Risk Assessment | Cholestasis, Intrahepatic - pathology | Down-Regulation | Liver - metabolism | Bile Acids and Salts - metabolism | Biomarkers - blood | Cholestasis, Extrahepatic - genetics | Gene Expression Regulation, Enzymologic | Cholagogues and Choleretics - pharmacokinetics | Cholesterol 7-alpha-Hydroxylase - genetics | Cholestasis, Intrahepatic - metabolism | Animals | Fibroblast Growth Factors - pharmacokinetics | Cholesterol 7-alpha-Hydroxylase - metabolism | Liver Neoplasms - metabolism | Mice | Cholestasis, Extrahepatic - metabolism | Australia | Cholestasis, Extrahepatic - drug therapy
Journal Article
Endocrinology, ISSN 0013-7227, 05/2014, Volume 155, Issue 5, pp. 2031 - 2040
Thyroid hormone (TH) regulates fibroblast growth factor 21 (FGF21) levels in the liver and in the adipose tissue. In contrast, peripheral FGF21 administration... 
THERMOGENESIS | PPAR-ALPHA | OBESITY | METABOLISM | DISEASE | ENDOCRINOLOGY & METABOLISM | MICE | BROWN ADIPOSE-TISSUE | TYPE-1 | EXPRESSION | FGF21 | Recombinant Proteins - therapeutic use | Hypothyroidism - metabolism | Fibroblast Growth Factors - adverse effects | Triiodothyronine - adverse effects | Hypothyroidism - physiopathology | Thyroxine - poisoning | Fibroblast Growth Factors - genetics | Thyroxine - blood | Hyperthyroidism - metabolism | Male | Muscle, Skeletal - metabolism | Hormone Replacement Therapy - adverse effects | Recombinant Proteins - adverse effects | Triiodothyronine - therapeutic use | Hyperthyroidism - chemically induced | Fibroblast Growth Factors - metabolism | Thyroxine - adverse effects | Liver - drug effects | Muscle, Skeletal - drug effects | Female | Thyroxine - therapeutic use | Fibroblast Growth Factors - therapeutic use | Recombinant Proteins - metabolism | Hyperthyroidism - blood | Liver - metabolism | Mice, Inbred C57BL | Recombinant Proteins - genetics | Hyperlipidemias - prevention & control | Mice, Knockout | Gene Expression Regulation - drug effects | Lipotropic Agents - therapeutic use | Triiodothyronine - blood | Animals | Lipotropic Agents - poisoning | Lipotropic Agents - adverse effects | Hyperlipidemias - etiology | Hypothyroidism - drug therapy | Lipid Metabolism - drug effects | Lipotropic Agents - blood | Adipose Tissue, Brown - drug effects | Adipose Tissue, Brown - metabolism | Mice | Hypothyroidism - blood | Energy Metabolism - drug effects | Thyroid-TRH-TSH
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2017, Volume 12, Issue 2, pp. e0171703 - e0171703
We evaluated the mitigating effects of fibroblast growth factor 4 and 7 (FGF4 and FGF7, respectively) in comparison with long acting protected graft copolymer... 
ADENOVIRUS-MEDIATED TRANSFER | ACUTE GASTROINTESTINAL SYNDROME | MYOCARDIAL INFARCT SIZE | MULTIDISCIPLINARY SCIENCES | ACID-BINDING PROTEIN | ORAL MUCOSITIS | ENDOTHELIAL-CELLS | CELL-SURVIVAL | RECEPTOR SPECIFICITY | RADIATION | THROMBOPOIETIN LEVELS | Fibroblast Growth Factors - adverse effects | Mice, Inbred C57BL | Kaplan-Meier Estimate | Fibroblast Growth Factor 4 - adverse effects | Gastrointestinal Tract - drug effects | Gastrointestinal Tract - radiation effects | Male | Polylysine - chemistry | Lethal Dose 50 | Gastrointestinal Tract - pathology | Fibroblast Growth Factor 7 - therapeutic use | Animals | Fibroblast Growth Factor 7 - adverse effects | Acute Radiation Syndrome - drug therapy | Fibroblast Growth Factor 4 - therapeutic use | Fibroblasts - drug effects | Radiation Injuries, Experimental - therapy | Female | Polymers - chemistry | Cell Proliferation - drug effects | Drug Delivery Systems - methods | Fibroblast Growth Factors - therapeutic use | Ionizing radiation | Care and treatment | Radiation injuries | Fibroblast growth factors | Research | Health aspects | Risk factors | Fibroblast growth factor | Laboratories | Radiation | Irradiated | Villus | Statistical methods | Lethality | Recovery | Toxicology | Jejunum | Polybenzimidazoles | Fibroblasts | Bone marrow | Bioindicators | Fibroblast growth factor receptor 7 | Colon | Growth factors | Radiation effects | Graft copolymers | Statistical analysis | Olefinic thermoplastic elastomers | Hematology | Histology | Pharmacology | Exposure | Bioavailability | Permeability | Citrulline | Fatty acids | Amifostine | Fibroblast growth factor 4 | Interleukin 18 | Irradiation | Biomarkers | Mice | Index Medicus
Journal Article